tbuckley/cabot-search huggingface dataset:
NIMG-68. MRI CAN DIAGNOSE LEPTOMENINGEAL METASTASES FROM GLIAL TUMORS BEFORE SYMPTOMS AND/OR SIGNS DEVELOP; EXAMPLES FROM A SERIES OF 40 CASES
Authors: Chris Dardis, Anthony Kuner, Kelly Milton, Peter Nakaji, Emad Youssef, Lynn S. Ashby, Jeffrey Ross
Journal: Neuro-Oncology (2016)

Leptomeningeal metastases (LM) are a rare and serious complication of glial tumors. Here we present the first case series of MRI features of LM in this setting. We sought to determine whether MRI had value as a screening exam - to detect disease beyond that suspected clinically (both spatially and temporally). We reviewed all literature relevant to MRI characteristics of LM in general. We reviewed records from our Institution over a 10 year period for cases of glioma with LM. All MRIs for each patient were reviewed by two of the authors together and the findings were confirmed independently by a third. Excluding those cases where LM was present at diagnosis, LM was at least probable on MRI before it was diagnosed clinically in 43% of cases. Spinal cord imaging was performed in 43% of patients. This revealed disease beyond that suspected clinically 59% of cases. A change in the pattern of inflammation was evident in those cases with LM in retrospect. They tended to have lower levels of protein and a higher proportion of lymphocytes. There are cases where MRI may be characteristic of LM before symptoms/ signs develop. This provides an opportunity for earlier intervention for this serious complication. Complete MRI of the neuraxis at the time of diagnosis of LM frequently shows disease not suspected clinically. As such, this should be performed where practical.
Importance of PI3 Kinase Family for Crosstalk between Chronic Lymphocytic Leukemia B Cells and the Stromal Microenvironment: Therapeutic Implications.
Authors: Matthias T.W. Niedermeier, Justyna Rawluk, Zachary Knight, Kevan Shokat, William G. Wierda, Michael J. Keating, Jan A. Burger
Journal: Blood (2007)
Possible Neuroprotective Effect of Erythropoietin in Acute Inflammation Induced by Exhaustive Exercise.
Authors: Ioannis Papassotiriou, Maria Tsironi, Evangelos Premetis, Katerina Kariyannis, Katerina Skenderi, Alexandra Stamoulakatou, Antonios Kattamis, George Chrousos
Journal: Blood (2005)
SF3B1 Mutations Are Detectable in 48.9% of Acute Myeloid Leukemia with Normal Karyotype (AML-NK) and ≥15% Ring Sideroblasts and Are Closely Related to FLT3-ITD and RUNX1 Mutations
Authors: Sabine Jeromin, Ulrike Bacher, Katharina Bayer, Frank Dicker, Christiane Eder, Annette Fasan, Vera Grossmann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach
Journal: Blood (2012)
The HDAC Inhibitors Trichostatin A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA) Exhibit Multiple Modalities of Benefit for the Vascular Pathology of Sickle Disease.
Authors: Robert P Hebbel, Gregory M. Vercellotti, Betty Pace, Anna Solovey, Rahn Kollander, Chine Abanonu, Julia Nguyen, Julie V. Vineyard, John D Belcher, Fuad Abdulla, Shade Osifuye, John W. Eaton, Robert Kelm, Arne Slungaard
Journal: Blood (2009)
Proteomic Profiling of Multiple Myeloma (MM) Cells Using iTRAQ and Label-Free Quantitative Proteomics for the Prediction of Complete or near Complete Response (CR/nCR) In Frontline Treatment with Lenalidomide, Bortezomib, and Dexamethasone
Authors: Dominik Dytfeld, Malathi Kandarpa, John R Strahler, Dattatreya Mellacheruvu, Suchitra Subramani, Stephanie J Kraftson, Lambert Ngoka, Alexey Nesvizhskii, Arun Sreekumar, Paul G Richardson, Andrzej J Jakubowiak
Journal: Blood (2010)
RNA: DNA Ratios in Human Tumors: Reply
Authors: Liba Kravetz de Srulijes, Ella Israeli, David Barzilai
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article RNA: DNA Ratios in Human Tumors: Reply Get access Liba Kravetz de Srulijes, Ph.D., Liba Kravetz de Srulijes, Ph.D. Dario and Matilde Beraha Center for Hormones in Cancer Research, Rambam University Hospital, Aba Khoushy School of Medicine Haifa, Israel Search for other works by this author on: Oxford Academic PubMed Google Scholar Ella Israeli, Ph.D., Ella Israeli, Ph.D. Dario and Matilde Beraha Center for Hormones in Cancer Research, Rambam University Hospital, Aba Khoushy School of Medicine Haifa, Israel Search for other works by this author on: Oxford Academic PubMed Google Scholar David Barzilai, M.D. David Barzilai, M.D. Dario and Matilde Beraha Center for Hormones in Cancer Research, Rambam University Hospital, Aba Khoushy School of Medicine Haifa, Israel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 4, October 1977, Page 1054, https://doi.org/10.1093/jnci/59.4.1054 Published: 01 October 1977
Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant <i>bcr-abl</i> positive lymphoid malignancies
Authors: O. Ottmann, F. Giles, B. Wassmann, A. Hochhaus, P. Rae, M. Beran, M. Albitar, L. Alland, M. Dugan, H. Kantarjian
Journal: Journal of Clinical Oncology (2005)

3015 Background: AMN107, a novel aminopyrimidine ATP-competitive inhibitor of Bcr-Abl. AMN107, is 10- to 50-fold more potent than imatinib against Bcr-Abl expressing cell lines, and is effective against most cell lines expressing imatinib-resistant Bcr-Abl mutants. In two p190-Bcr-Abl ALL cell lines, AMN107 was 30–40 times more potent than imatinib in inhibiting cellular proliferation and in inhibiting phosphorylation of p190 Bcr-Abl tyrosine kinase in cell lines and primary ALL cells. Methods: In an ongoing phase I study, AMN107 was given orally, once or twice daily dosing schedule. Results: Fifteen of 67 total pts entered had lymphoid disease: lymphoid blastic phase CML (CML LBP) 7 pts; Ph+ acute lymphocytic leukemia (Ph+ ALL) 8 patients. Median age was 53 years (range 28–80). AMN doses were: QD dose cohorts (mg/day); 50 (1 pt), 100 (2 pts), 200 (3 pts), 400 (1 pt), 600 (2 pts), 800 (4 pts), 1200 (1 pt); BID dose cohort; 400 mg BID (1 pt). Pts have been treated for 15 to 89 days. In the overall cohort, possible AMN-related Grade 3 or 4 hematologic adverse events were observed in 5/67 patients (3 responded) at doses ≥ 200 mg: Possible AMN-related non-hematologic Grade 3/4 events were: 600 mg, G3 skin rash (1 pt); ≥ 800 mg, G3 SGOT and/or SGPT elevations (2 pts), G3 indirect hyperbilirubinemia (2 pts), and at 1200 mg, G2 pancreatitis (1 pt). Clinical activity has been observed in 5 of the 14 with lymphoid disease treated with doses of ≥ 600 mg: hematological improvement (1 pt, Ph+ ALL), peripheral responses (2 pts, LBP), and bone marrow responses (marrow response/no evidence of leukemia, 2 pts, LBP) 1 pt with LBP had a cytogenetic CR. Mutational data are available for 3 of the responding patients: Y253H (hematologic improvement), T315I (peripheral response), and E355G (marrow response). Pharmacokinetic (PK) studies showed steady state was generally reached by day 8. Both Cmax and AUC were dose proportional from 50 to 400 mg with a median Tmax of 3 hours. The apparent half-life was 16 hours. Conclusions: AMN107 has significant activity in patients treated with ≥ 600 mg per day in imatinib-resistant CML LBP or Ph+ ALL Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis Novartis
Assessment of the Aryl Hydrocarbon Receptor Gene as a Therapeutic Target in Childhood T-Lineage Acute Lymphoblastic Leukemia.
Authors: Marrit Meier, Monique L. den Boer, Mathilde J.C. Broekhuis, Ronald W. Stam, Elisabeth R. van Wering, Gritta E. Janka-Schaub, Rob Pieters
Journal: Blood (2005)
Hesk Ratio: A Complementary Tool for the Diagnosis of Myelodysplastic Syndromes and a Novel Method for Flow Cytometry Analysis
Authors: Evgenia Verigou, Georgia Kolliopoulou, Nikoleta Smirni, Elisavet Hala, Polixeni Lampropoulou, Sophia Mouzopoulou, Eirini Konstantinidou, Foteini Kalogianni, Panagiotis Zikos, Ioannis Starakis, Elena E. Solomou, Argiris S Symeonidis, Marina Karakantza
Journal: Blood (2012)
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection
Authors: Roberto Guariglia, Stefano Luminari, Amalia De Renzo, Emilio Iannitto, Matteo Dell’Olio, Samantha Pozzi, Teresa Pierri, Lucia D’Amato, Antonio Traficante, Stefano Sacchi, Pellegrino Musto
Journal: Blood (2008)
ANGI-06. MMP9 AND MMP2 EXHIBIT DISTINCT INTRATUMORAL EXPRESSION PATTERN IN PAIRED INITIAL AND RECURRENT GLIOBLASTOMA (GB)
Authors: Emilie Denicolai, Dominique Figarella-Branger, Olivier Chinot, Emeline Tabouret
Journal: Neuro-Oncology (2016)

We recently showed that a low MMP9 and a high MMP2 plasma level at baseline were associated with high response rate and prolonged survival in recurrent GB treated with bevacizumab (Tabouret, Neuro Oncol 2014, 2015). In newly diagnosed GB, MMP9 but not MMP2 predict bevacizumab overall survival benefit in patients included in Avaglio trial (Chinot, ASCO 2016). However, biological rational of these results remains unclear. Our objective was to explore intratumoral expression of MMP9 and MMP2 and their changes between initial diagnosis and recurrence of GB. Paired parafin tumor tissues from initial and recurrent surgeries were available for 18 patients with GB treated with radiotherapy/temozolomide (RT/TMZ) without bevacizumab (BEV) upfront and for 4 patients treated with BEV upfront (N=2) or at first relapse (N=2). For RT/TMZ patients at initial diagnosis, MMP9 staining was mainly located in endothelial cells in microvascular proliferation cells and in some circulating cells within vessels. No staining was observed in GB cells nor extracellular matrix. In contrast, MMP2 staining was mainly located in GB cells and extracellular matrix, with minor staining observed in endothelial cells and no staining in the microvascular proliferation cells. At relapse, after RT/TMZ, similar pattern of expression was observed for MMP9 and MMP2, although a decreased expression of MMP9 in the microvascular proliferation cells was observed. After BEV treatment, MMP9 expression was also decreased in the microvascular proliferation cells in 3/4 patients and increased in circulating cells within vessels in 4/4 patients. MMP2 expression showed no consistent change. In conclusion, intratumoral MMP9 and MMP2 expressions showed distinct expression pattern in GB patients suggesting distinct roles. After RT/TMZ, no change was observed while after BEV MMP9 expression may change. These results should be confirmed in a larger cohort.
High Efficiency and Tolerance of Temozolomide in Relapse/Refractory Primary Intra-Ocular Lymphoma (R/R PIOL). a Retrospective Multicentric Study from the LOC Network
Authors: Marine Baron, Emmanuel Gyan, Hélène Merle-Beral, Veronique Leblond, Nathalie Cassoux, Valerie Touitou, Bahram Bodaghi, Adil Darugar, Sylvain Choquet
Journal: Blood (2014)
Distinctive Patterns of BCL6 Molecular Alterations in Different Subsets of Diffuse Large B-Cell Lymphoma and Their Functional Consequences.
Authors: J. Iqbal, T. C. Greiner, K. Patel, J. Ji, B. J. Dave, D. E. Horsman, Y. Shen, D. D. Weisenburger, E. Campo, A. Rosenwald, R. D. Gascoyne, E. S. Jaffe, G. Ott, J. Delabie, L. Rimsza, T. McKeithan, L. M. Staudt, W. C. Chan
Journal: Blood (2005)
Linking long non-coding RNAs and SWI/SNF complexes to chromatin remodeling in cancer
Authors: Yanyan Tang, Jinpeng Wang, Yu Lian, Chunmei Fan, Ping Zhang, Yingfen Wu, Xiayu Li, Fang Xiong, Xiaoling Li, Guiyuan Li, Wei Xiong, Zhaoyang Zeng
Journal: Molecular Cancer (2017)

Chromatin remodeling controls gene expression and signaling pathway activation, and aberrant chromatin structure and gene dysregulation are primary characteristics of human cancer progression. Recent reports have shown that long non-coding RNAs (lncRNAs) are tightly associated with chromatin remodeling. In this review, we focused on important chromatin remodelers called the switching defective/sucrose nonfermenting (SWI/SNF) complexes, which use the energy of ATP hydrolysis to control gene transcription by altering chromatin structure. We summarize a link between lncRNAs and the SWI/SNF complexes and their role in chromatin remodeling and gene expression regulation in cancer, thereby providing systematic information and a better understanding of carcinogenesis.
Inhibition of NOTCH1 Signaling and Glucocorticoid Therapy in T-ALL
Authors: Pedro Jose Real, Valeria Tosello, Teresa Palomero, Mireia Castillo, Catherine Sawai, Maria Luisa Sulis, Jules P.P. Meijerink, Giuseppe Basso, Iannis Aifantis, Carlos Cordon-Cardo, Adolfo A. Ferrando
Journal: Blood (2008)
Predictive Value of Clonal Peripheral Blood γTCR Rearrangement in Patients with Peripheral T-Cell Lymphoma.
Authors: Christian Schuetzinger, Harald Esterbauer, Cathrin Skrabs, Martin Uffmann, Markus Raderer, Alexander Hauswirth, Alexander Gaiger, Christine Mannhalter, Karin Dieckmann, Oswald Wagner, Ulrich Jaeger
Journal: Blood (2006)
Neoadjuvant treatment of a duodenal GIST revealed a new imatinib-sensitive exon 11 c-KIT-mutation
Authors: V. Perfetti, S. Delfanti, L. Pugliese, R. Riboni, E. Dallera, M. Lucioni, P. Rognoni, F.S. Latteri, P. Pedrazzoli, A. Pietrabissa
Journal: Annals of Oncology (2016)
Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis
Authors: Anuj Mahindra, Paul G Richardson, Parameswaran Hari, Aliyah R. Sohani, Jacob P. Laubach, Jill Burke, Sarah Kaster, Christine Connolly, Linda Rivera, Paulette Jacobs, Ayman Saad, Kathleen Colson, Irene Ghobrial, Robert L. Schlossman, Jennifer Adams, Wendy Makrides, Edie Weller, Nikhil C. Munshi, Kenneth C. Anderson, Noopur Raje
Journal: Blood (2010)
CLL-Like MBL In the General Population Persist Over Time, without Clinical Progression, Though Carrying the Same Cytogenetic Abnormalities of CLL
Authors: Paolo Ghia, Claudia Fazi, Lorenza Pecciarini, Lydia Scarfò, Francesca Cottini, Antonis Dagklis, Agnieszka Janus, Cristina Scielzo, Cinzia Sala, Daniela Toniolo, Federico Caligaris-Cappio
Journal: Blood (2010)
Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs
Authors: David L. Mack, Karine Poulard, Melissa A. Goddard, Virginie Latournerie, Jessica M. Snyder, Robert W. Grange, Matthew R. Elverman, Jérôme Denard, Philippe Veron, Laurine Buscara, Christine Le Bec, Jean-Yves Hogrel, Annie G. Brezovec, Hui Meng, Lin Yang, Fujun Liu, Michael O’Callaghan, Nikhil Gopal, Valerie E. Kelly, Barbara K. Smith, Jennifer L. Strande, Fulvio Mavilio, Alan H. Beggs, Federico Mingozzi, Michael W. Lawlor, Ana Buj-Bello, Martin K. Childers
Journal: Molecular Therapy (2017)

X-linked myotubular myopathy (XLMTM) results from MTM1 gene mutations and myotubularin deficiency. Most XLMTM patients develop severe muscle weakness leading to respiratory failure and death, typically within 2 years of age. Our objective was to evaluate the efficacy and safety of systemic gene therapy in the p.N155K canine model of XLMTM by performing a dose escalation study. A recombinant adeno-associated virus serotype 8 (rAAV8) vector expressing canine myotubularin (cMTM1) under the muscle-specific desmin promoter (rAAV8-cMTM1) was administered by simple peripheral venous infusion in XLMTM dogs at 10 weeks of age, when signs of the disease are already present. A comprehensive analysis of survival, limb strength, gait, respiratory function, neurological assessment, histology, vector biodistribution, transgene expression, and immune response was performed over a 9-month study period. Results indicate that systemic gene therapy was well tolerated, prolonged lifespan, and corrected the skeletal musculature throughout the body in a dose-dependent manner, defining an efficacious dose in this large-animal model of the disease. These results support the development of gene therapy clinical trials for XLMTM.Graphical abstract
First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study
Authors: M. Bersanelli, F. Maines, G. Facchini, F. Gelsomino, F. Zustovich, M. Santoni, E. Verri, U. De Giorgi, C. Masini, F. Morelli, M.G. Vitale, T. Sava, G. Prati, C. Librici, A.P. Fraccon, G. Fornarini, M. Maruzzo, F. Leonardi, O. Caffo, S. Buti
Journal: Annals of Oncology (2016)
ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy
Authors: A. Bossi, D. Dearnaley, M. McKenzie, E. Baskin-Bey, R. Tyler, B. Tombal, S.J. Freedland, M. Roach, A. Widmark, A.P. Dicker, T. Wiegel, N. Shore, M. Smith, M. Yu, T. Kheoh, S. Thomas, H.M. Sandler
Journal: Annals of Oncology (2016)
Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
Authors: R.J. Motzer, T. Choueiri, J. Larkin, L. Albiges, J.B. Haanen, M. Schmidinger, M.B. Atkins, M. Mariani, M. Shnaidman, A. Di Pietro, B.I. Rini
Journal: Annals of Oncology (2016)
Multi-centre randomized controlled study comparing adjuvant vs neo-adjuvant chemotherapy with docetaxel plus carboplatin in resectable stage IB to IIIA NSCLC: final results of CSLC0501
Authors: Y.-L. Wu, X.-N. Yang, W. Zhong, X. Ben, G.-B. Qiao, Q. Wang, C. Wang, H.-H. Luo, Z. Wang, H.-H. Yan
Journal: Annals of Oncology (2016)
Abstract 19670: Adipose-derived Mesenchymal Stem Cells Attenuate Pulmonary Microvascular Hyperpermeability After Smoke Inhalation
Authors: Koji Ihara, Satoshi Fukuda, Baigalmaa Enkhtaivan, Raul Trujillo, Ernesto Lopez, Robert A Cox, Hal K Hawkins, David N Herndon, Donald S Prough, Perenlei Enkhbaatar
Journal: Circulation (2015)

Pulmonary edema is a hallmark of acute respiratory distress syndrome (ARDS). Smoke inhalation causes ARDS, significantly increasing the mortality of burn patients. Mesenchymal stem cells (MSCs) exert potent anti-inflammatory properties. The goal of the present study was to test the safety and efficacy of MSCs in a well-characterized clinically relevant ovine model of ARDS. Methods: Female sheep (30-40 kg) were surgically prepared 5-7 days prior the study. ARDS was induced by cooled cotton smoke inhalation. Following the injury, sheep were ventilated, resuscitated with lactated Ringer’s solution and cardiopulmonary hemodynamics was monitored for 48 h in a conscious state. Pulmonary microvascular hyper-permeability was assessed by measuring lung lymph flow, extravascular lung water content, protein in plasma and lung lymph. Sheep were randomly allocated to two groups: 1) MSCs: infused with 5 million/kg of intravenous MSCs over 30min starting 1 h post-injury, n=5; 2) control, treated with a vehicle in a similar pattern (200ml of PlasmaLyte A), n=5. Results: Lung lymph flow, an index of pulmonary transvascular fluid flux was ~7-fold increased in control sheep compared to baseline. This was associated with a significant protein decrease in plasma and its increase in lung lymph. The treatment with MSCs significantly attenuated these changes (Table). Moreover, the treatment with MSCs almost reversed increased pulmonary vascular permeability index {(lung lymph proteinхlung lymph flow)/plasma protein} and reduced lung water content (Lung wet-to-dry weight ratio). Pulmonary gas exchange was significantly improved by MSCs (PaO2/FiO2 was 406±101 in MSCs and 262±127 in control at 24 hrs, p&lt;0.05). Infusion of the MSCs did not affect pulmonary artery pressure and other hemodynamic variables. Conclusions: MSCs infusion was well tolerated. The results suggest that intravenous MSCs modulate pulmonary microvascular hyper-permeability and prevent onset of ARDS.
Clinical Features and Prognostic Impact of CD56 Expression in Acute Promyelocytic Leukemia: Long Term Follow up Data From the Japan Adult Leukemia Study Group(JALSG) APL97,
Authors: Takaaki Ono, Akihiro Takeshita, Yuji Kishimoto, Hitoshi Kiyoi, Masaya Okada, Takahiro Yamauchi, Motohiro Tsuzuki, Kentaro Horikawa, Mitsuhiro Matsuda, Katsuji Shinagawa, Fumihiko Monma, Shigeki Ohtake, Chiaki Nakaseko, Masatomo Takahashi, Fumiharu Yagasaki, Yukihiko Kimura, Hiroyuki Fujita, Masako Iwanaga, Norio Asou, Kazunori Ohnishi, Tomoki Naoe
Journal: Blood (2011)
Relationships Between Type 2 Diabetes, Neuropathy, and Microvascular Dysfunction: Evidence From Patients With Cryptogenic Axonal Polyneuropathy
Authors: Anna L. Emanuel, Mariska D. Nieuwenhoff, Erica S. Klaassen, Ajay Verma, Mark H.H. Kramer, Rob Strijers, Alexander F.J.E. Vrancken, Etto Eringa, Geert Jan Groeneveld, Erik H. Serné
Journal: Diabetes Care (2017)

OBJECTIVE This study investigated whether the relationship between neuropathy and microvascular dysfunction in patients with type 2 diabetes is independent of diabetes-related factors. For this purpose, we compared skin microvascular function in patients with type 2 diabetes with that of patients with cryptogenic axonal polyneuropathy (CAP), a polyneuropathy of unknown etiology. RESEARCH DESIGN AND METHODS Cross-sectional information was collected from 16 healthy controls (HCs), 16 patients with CAP, 15 patients with type 2 diabetes with polyneuropathy (DPN), and 11 patients with type 2 diabetes without polyneuropathy. Axonal degeneration was assessed with skin biopsy and nerve conduction studies. Microvascular skin vasodilation was measured using laser Doppler fluxmetry combined with iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP). RESULTS Patients with CAP and DPN demonstrated a similar decrease in intraepidermal nerve fiber density and sural sensory nerve action potential compared with HCs. The vasodilator response to ACh was similar among patients with CAP (relative mean difference based on log values 13.3%; 95% CI −35.0 to 97.7%; P = 0.652) but was lower in the patients with diabetes with neuropathy (157.5%; 42.0–366.7%; P = 0.003) and without neuropathy (174.2%; 44.2–421.3%; P = 0.003) compared with HCs. No significant differences were found between the groups of patients with diabetes (P = 0.845). The vasodilator response to SNP was not significantly different among the groups (P = 0.082). CONCLUSIONS In this study, endothelium-dependent vasodilation was reduced in patients with type 2 diabetes regardless of the presence of polyneuropathy, whereas microvascular vasodilation was normal in patients with CAP. These data suggest that in type 2 diabetes, neuropathy does not contribute to impaired microvascular endothelium-dependent vasodilation and vice versa. In addition, this study suggests that impaired microvascular vasodilation does not contribute to CAP.
P01.03 mTORC1 activation sensitizes human malignant glioma cells to hypoxia-induced cell death by increasing O2-consumption
Authors: A. L. Thiepold, M. Foltyn, H. Urban, S. Heller, S. Dröse, P. N. Harter, M. Mittelbronn, J. P. Steinbach, M. W. Ronellenfitsch
Journal: Neuro-Oncology (2016)

polyneuropathy occurs already early in treatment after application of only 1 to 6 doses in a substantial number of patients.Toxicity of the complete treatment protocol including adjuvant chemotherapy will be analysed and presented elsewhere.
Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2
Authors: H. Rugo, V. Dieras, K.A. Gelmon, R. Finn, D. Slamon, M. Miguel, P. Neven, J. Ettl, Y. Shparyk, A. Mori, D.R. Lu, H. Bhattacharyya, C.H. Bartlett, S. Iyer, S. Johnston, N. Harbeck
Journal: Annals of Oncology (2016)
A Reduced Rate of Leukaemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for Acute Myeloid Leukaemia but Not Other Haematological Malignancies Is Associated with Donor KIR Genes 2DL5A, 2DS1 and 3DS1.
Authors: Kate Stringaris, Sharon Adams, Marcela Uribe, Rhoda Eniafe, Colin Wu, Bipin N. Savani, A. John Barrett
Journal: Blood (2009)